Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Overview of attention for article published in Leukemia & Lymphoma, April 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Readers on

mendeley: 63 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 3,379 followers.

New article: Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. https://t.co/Yllrr6aVEr #MMSM #MultipleMyeloma #hematology https://t.co/ipHjmw8VqY

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. #lymphoma #lymsm https://t.co/BrYhr9IxgY

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.